Drug intelligence / Profile preview

TQB2618 + TQB2450

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TQB2618 + TQB2450 is an investigational combination therapy being evaluated for the treatment of advanced solid tumors. The regimen consists of two agents: - **TQB2450 (benmelstobart)**, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets programmed death-ligand 1 (PD-L1), thereby blocking its interaction with PD-1 and CD80 to enhance antitumor immune responses. - **TQB2618**, for which detailed public information on mechanism or modality is not available, but it is being studied in combination with TQB2450 in early-phase clinical trials for advanced malignancies. The combination aims to improve efficacy by leveraging immune checkpoint inhibition via PD-L1 blockade and potentially additional mechanisms from TQB2618. The primary developer and manufacturer identified for these agents is Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of Sino Biopharmaceutical Limited[7][8]. Clinical studies are ongoing, primarily in China, focusing on safety, pharmacokinetics, receptor occupancy, immunogenicity, and preliminary antitumor activity[1][2].

Brand names: benmelstobart
Other names: none

Targets

HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on TQB2618 + TQB2450.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQB2618 + TQB2450.

Explore the full profile